Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Immunotherapy
; 13(2): 177-184, 2021 02.
Article
en En
| MEDLINE
| ID: mdl-33225803
Despite the success of antiretroviral therapy in suppressing HIV to an undetectable level in the blood and improving patients' quality of life, HIV persists in antiretroviral therapy-treated patients and threatens their lives. Anti-HIV chimeric antigen receptor (CAR) T cells could offer a cure by recognizing and killing virus-producing cells in an Env-specific manner. In this review, the authors summarize several important aspects of the development of anti-HIV CAR T cells, with a special focus on the evolution of CAR design for enhanced potency and targeting specificity, and also outline the challenges that still need to be addressed to take anti-HIV CAR T cells from a hopeful approach to a real HIV cure.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfocitos T
/
Infecciones por VIH
/
Inmunoterapia Adoptiva
/
Desarrollo de Medicamentos
/
Receptores Quiméricos de Antígenos
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2021
Tipo del documento:
Article